(MedPage Today) — New data from a phase IIb trial extension study suggested that investigational neflamapimod led to significant improvements on key outcomes in people with dementia with Lewy bodies (DLB).
In the RewinD-LB extension study, neflamapimod…
Source link : https://www.medpagetoday.com/meetingcoverage/ctad/118871
Author :
Publish date : 2025-12-06 20:13:00
Copyright for syndicated content belongs to the linked Source.
